#USA #Marietta #Airway Therapeutics #Zelpultide Alfa #Joe Todisco

Airway Therapeutics Expands Leadership with New Board Appointment

In a strategic move, Airway Therapeutics, Inc., known for its innovative approaches in the biopharmaceutical landscape, has appointed Joe Todisco as a member of its Board of Directors effective April 13, 2026. This decision is poised to significantly enhance the company's leadership capabilities as it advances its clinical pipelines and prepares for commercialization efforts.

Joe Todisco: A Leader in Biopharma

Mr. Todisco brings with him over 20 years of extensive experience in the pharmaceutical and biotechnology fields. His impressive track record includes roles in commercial strategy and corporate development, indicating that he is well-equipped to steer Airway Therapeutics toward its strategic objectives. Chairman and CEO of Airway Therapeutics, Dr. Marc Salzberg, expressed confidence in Todisco's capacity to guide the company as it navigates the complexities of late-stage product development, particularly focusing on its lead candidate, zelpultide alfa.

"Joe's wealth of knowledge in specialty pharmaceuticals will be invaluable for our progression toward pivotal stages of our pipeline," Dr. Salzberg stated. Zelpultide alfa is aimed at preventing bronchopulmonary dysplasia (BPD) in very preterm infants, addressing a currently unmet medical need within pediatric healthcare.

Enhancing Growth and Innovation

With Todisco's addition, the leadership team anticipates boosting growth not only by advancing zelpultide alfa but also by leveraging Todisco's vast experience in commercializing hospital-based products. Having honed his skills at prestigious organizations like Amneal Pharmaceuticals, where he served as Chief Commercial Officer, and as co-founder of Gemini Laboratories, he represents a solid strategic asset for Airway Therapeutics.

"Joining Airway at this pivotal moment in its development is an exciting opportunity. I am eager to collaborate with the team to capitalize on its innovative pipeline, particularly the potential of zelpultide alfa to fulfill critical medical needs," remarked Mr. Todisco.

A Focus on Innovation and Future Growth

Airway Therapeutics continues to strive for excellence in developing biologic therapies aimed at respiratory, inflammatory, and infectious diseases. The company’s forward-thinking methodology, combined with Todisco's operational insights, is set to accelerate the launch of zelpultide alfa, provided it gains the necessary approvals.

The company also aims to apply zelpultide alfa in broader contexts beyond its initial pediatric focus, targeting multiple age groups and other disease conditions as part of its long-term strategy to improve healthcare outcomes for vulnerable populations.

Conclusion

The appointment of Joe Todisco marks a significant turning point for Airway Therapeutics, further bolstering its capability to lead in the biopharmaceutical arena. As the company harnesses his expertise and vision, it embarks on an ambitious journey to redefine treatment methodologies in respiratory illnesses. For more insights and updates on Airway Therapeutics, interested parties can visit their official website here.

In conclusion, as the biopharmaceutical landscape evolves, companies like Airway Therapeutics are committed to advancing groundbreaking therapies that not only promise to improve patient care but also drive the future of medicine forward.